Avandia (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. Avandia is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). The New England Journal of Medicine recently published a report that links the diabetes drug Avandia with an increased heart attack risk. According to the report, the increased risk is as high as 43 percent. This works out to about one heart attack per 1000 patients. About 1 million diabetics in the U.S. alone take Avandia to help control their blood sugar. This means that thousands of diabetics could be at risk from Avandia. Avandia is the No. 2 seller for GlaxoSmithKline (GSK), a British company. About 1 million Americans take the pill, which generated about $3 billion in sales last year.
Do not change medications without first consulting your doctor.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.